Healthcare -
Biotechnology - NASDAQ - US
$ 4.02
-5.41 %
$ 34.7 M
Market Cap
-0.32
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Karyopharm Therapeutics Inc.
| Current Assets | 156 M |
| Cash & Short-Term Investments | 109 M |
| Receivables | 30.8 M |
| Other Current Assets | 17 M |
| Non-Current Assets | 7.93 M |
| Long-Term Investments | 0 |
| PP&E | 6.28 M |
| Other Non-Current Assets | 1.64 M |
| Current Liabilities | 92.3 M |
| Accounts Payable | 5.11 M |
| Short-Term Debt | 24.9 M |
| Other Current Liabilities | 62.3 M |
| Non-Current Liabilities | 258 M |
| Long-Term Debt | 170 M |
| Other Non-Current Liabilities | 88.5 M |
EFFICIENCY
Earnings Waterfall
Karyopharm Therapeutics Inc.
| Revenue | 145 M |
| Cost Of Revenue | 6.01 M |
| Gross Profit | 139 M |
| Operating Expenses | 259 M |
| Operating Income | -119 M |
| Other Expenses | -43 M |
| Net Income | -76.4 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Karyopharm Therapeutics Inc.
| Net Income | -76.4 M |
| Depreciation & Amortization | -2.16 M |
| Capital Expenditures | -142 K |
| Stock-Based Compensation | 18.4 M |
| Change in Working Capital | -302 K |
| Others | -69.5 M |
| Free Cash Flow | -128 M |
Wall Street Analysts Price Targets
Karyopharm Therapeutics Inc.
Wall Street analysts predict an average 1-year price target for KPTI of $7.5 , with forecasts ranging from
a
low of
$3 to a high of $14 .
KPTI Lowest Price Target
Wall Street Target
3 USD
-25.37%
KPTI Average Price Target
Wall Street Target
7.5 USD
86.57%
KPTI Highest Price Target
Wall Street Target
14 USD
248.26%
4. DIVIDEND
ANALYSIS
KPTI does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Karyopharm Therapeutics Inc.
Sold
0-3 MONTHS
1.68 K USD 1
3-6 MONTHS
27.5 K USD 4
6-9 MONTHS
9.45 K USD 1
9-12 MONTHS
24.1 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , July 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 666 restricted stock units (RSUs) to two newly-hired employees.
prnewswire.com
- 3 weeks ago
Karyopharm to Present at the Jefferies Global Healthcare Conference
NEWTON, Mass. , June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m.
prnewswire.com
- 1 month ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass. , June 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 566 restricted stock units (RSUs) to two newly-hired employees.
prnewswire.com
- 1 month ago
Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now
Karyopharm Therapeutics (KPTI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
zacks.com
- 1 month ago
Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 521.6% in Karyopharm Therapeutics (KPTI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
zacks.com
- 2 months ago
Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
NEWTON, Mass. , May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m.
prnewswire.com
- 2 months ago
Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting
NEWTON, Mass. , May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy.
prnewswire.com
- 2 months ago
These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results
Karyopharm Therapeutics Inc. KPTI reported mixed financial results for the first quarter on Monday.
benzinga.com
- 2 months ago
Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript
Karyopharm Therapeutics Inc. (NASDAQ:KPTI ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Brendan Strong - Senior Vice President, Investor Relations & Corporate Communications Richard Paulson - President & Chief Executive Officer Reshma Rangwala - Chief Medical Officer & Head, Research Sohanya Cheng - Chief Commercial Officer & Head, Business Development Lori Macomber - Chief Financial Officer & Treasurer Conference Call Participants Colleen Kusy - Baird Ted Tenthoff - Piper Sandler Peter Lawson - Barclays Albert Agustinus - Leerink Partners Operator Good afternoon. My name is Chloe, and I will be your conference operator today.
seekingalpha.com
- 2 months ago
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.77 per share versus the Zacks Consensus Estimate of a loss of $4.21. This compares to loss of $4.80 per share a year ago.
zacks.com
- 2 months ago
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification
– New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns of Expired 80 mg and 100 mg Units – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million, Including U.S. XPOVIO Net Product Revenue Guidance of $115 Million to $130 Million – – Company is Exploring Various Alternatives to Extend Cash Runway – – Conference Call Scheduled for Today at 4:30 p.m. ET – NEWTON, Mass.
prnewswire.com
- 2 months ago
Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025
-- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass.
prnewswire.com
- 2 months ago
8. Profile
Summary
Karyopharm Therapeutics Inc. KPTI
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 34.7 M
Dividend Yield
0.00%
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Contact
85 Wells Avenue, Newton, MA, 02459
https://www.karyopharm.com
IPO
Date
Nov. 6, 2013
Employees
279
Officers
Ms. Kristin Abate
Vice President, Chief Accounting Officer & Assistant Treasurer
Dr. Mansoor Raza Mirza M.D.
Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Mr. James Accumanno J.D.
Chief Compliance Officer
Dr. Reshma Rangwala M.D., Ph.D.
Executive Vice President, Chief Medical Officer & Head of Research
Ms. Sohanya Cheng M.B.A.
Executive Vice President, Chief Commercial Officer & Head of Business Development
Dr. Sharon Shacham M.B.A., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Ms. Lori A. Macomber CPA
EVice President, Chief Financial Officer & Treasurer
Mr. Brendan Twohig Strong
SVice President of Investor Relations & Corporate Communications
Mr. Michael J. Mano J.D.
Senior Vice President, General Counsel & Secretary
Mr. Richard A. Paulson M.B.A.
President, Chief Executive Officer & Director